MichaelNNeelyMDMSc

Pediatric Infectious Disease • Los Angeles, CA

Professor of Pediatrics, Clinical Scholar, University of Southern California

Join to view full profile

Dr. Neely is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Neely's full profile

Already have an account?

Office
Laboratory of Applied Pharmacokinetics
4650 Sunset Blvd, MS #176
Los Angeles, CA 90027
Phone+1 323-361-2509

Education & Training

University of Southern CaliforniaMD, Clinical and Biomedical Investigations, 2011
University Hospitals of ClevelandFellowship, 1999 - 2002
Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 1996 - 1999
University of California, Davis, School of MedicineClass of 1996
University of CaliforniaBA, Neurobiology, Highest Distinction Honors, 1991

Publications & Presentations

PubMed

22 citations
Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children
Hanen Marsit, Michaël Philippe, Michael Neely, Teresa Rushing, Yves Bertrand
Clinical Pharmacokinetics. 2020-03-11
91 citations
Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin.
Xia Sheng, Jean-Hugues Parmentier, Jonathan Tucci, Hua Pei, Omar Cortez-Toledo
Molecular Cancer Research. 2017-12-01
25 citations
Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell tra...
Michaël Philippe, Michael Neely, Teresa Rushing, Yves Bertrand, Nathalie Bleyzac
Bone Marrow Transplantation. 2019-03-01

Journal Articles

Maximal Concentration of Intravenous Busulfan as a Determinant of Veno-Occlusive Disease: A Pharmacokinetic-Pharmacodynamic Analysis in 293 Hematopoietic Stem Cell Tra...
Michael Neely, MD, Nature
Neurodevelopment and in utero antiretroviral exposure of HIV-‐exposed uninfected infants.
Williams PL, Marino M, Malee K, Brogly S, Hughes MD, Mofenson LM, Pediatrics;125(2):e250-?60
Comment: Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients.
Goutelle S, Neely MN, Bleyzac N, Ann Pharmacother;45(9):1171-?2
Infection control in pediatric hospitals.
Neely MN, Totzis P, Curr Op Peds;14:449-?53
Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time.
Neely MN, Schreiber JA, Pediatrics;107(2):404-?6
The exciting future of antifungal therapy.
Neely MN, Ghannoum MA, Eur J Clin Microbiol Infect Dis;19:897-?914
Pharmacokinetic characteristics of caspofungin in two pediatric liver transplant patients.
Neely MN, Blumer JB, Cur Ther Res;64(2):127-?36
Long-‐term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.
Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team, Clin Infect Dis;46(11):1751-?60
Pharmacokinetics and safety of caspofungin in young children.
Neely MN, Jafri HS, Seibel N, Knapp K, Adamson P, Strohmaier K, Sheng B, Bradshaw S, Sun P, Stone J, Kartsonis N, Antimicrob Agents Chemother;53(4):1450-?6
The role of cognitive functioning in medication adherence of children and adolescents with HIV infection.
Malee K, Williams PL, Montepiedra G, Nichols S, Sirois PA, Storm D, Farley J, Kammerer B; PACTG 219C Team, J Pediatr Psychol;34(2):164-?75
Incidence of noninfectious conditions in perinatally HIV-‐infected children and adolescents in the HAART era.
Nachman SA, Chernoff M, Gona P, Van Dyke RB, Dankner WM, Seage GR 3rd, Oleske J, Williams PL; PACTG 219C Team, Arch Pediatr Adolesc Med;163(2):164-?71
Impact of HAART and CNS-‐penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents.
Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR 3rd; International Maternal Pediatric Adolescent AIDS Clinical Trials 219/219C Study Team, AIDS;23(14):1893-?901
Impact of medications prescribed for treatment of attention-‐deficit hyperactivity disorder on physical growth in children and adolescents with HIV.
Sirois PA, Montepiedra G, Kapetanovic S, Williams PL, Pearson DA, Malee K, Garvie PA, Kammerer BL, Nichols SL, Nozyce ML, Mintz M, Mitchell WG, Oleske JM, J Dev Behav Pediatr30(5):403-?12
The use of second-‐ generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV.
Kapetanovic S, Aaron L, Montepiedra G, Sirois PA, Oleske JM, Malee K, Pearson DA, Nichols SL, Garvie PA, Farley J, Nozyce ML, Mintz M, Williams PL, AIDS Patient Care STDS;23(11):939-?47
Human genetic variation, population pharmacokinetic – dynamic models, Bayesian feedback control, and maximally precise individualized drug dosage regimens.
Jelliffe R, Schumitzky A, Bayard D, Leary R, Botnen A, Van Guilder M, Bustad A, Neely M, Current Pharmacogenomics and Personalized Medicine; 7: 249-?262
Seven “Pillars of Wisdom” for maximally precise therapeutic drug management.
Jelliffe R, Neely MN, Klin Farmakol Farm;24(1):7-?10
Quantification of alendronate in diseased jaw bone of patients with bisphosphonate-‐related jaw osteonecrosis by energy dispersive x-‐ray spectroscopy.
Schaudinn C, Gorur A, Webster P, Jones AC, Neely MN, Jelliffe RW, Le AD, Sedghizadeh PP, Oral Surg Oral Med Oral Pathol
Can TDM improve pharmacotherapy of HIV infection in adolescents?
Rakhmanina N, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN, Ther Drug Monit;32(3):273-?81
Phase I/II, open-‐label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-‐135) polysaccharide diphtheria toxoid conjugate vaccine in human ...
Siberry GK, Williams PL, Lujan-?Zilbermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, Jean-?Philippe P, Kabat W, Nachman S; IMPAACT P1065 ..., Pediatr Infect Dis J;29(5):391-?6
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-‐infected children 7 to 12 years old.
Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA 3rd, Read JS, Handelsman EL, Nowak B, Sattler CA, Saah A, Radley DR, Esser MT, Weinberg A; IMPAACT P1047 Protocol Team, J Acquir Immune Defic Syndr.1;55(2):197-?204
Mode of delivery and infant respiratory morbidity among infants born to HIV-‐1-‐infected women.
Livingston EG, Huo Y, Patel K, Brogly SB, Tuomala R, Scott GB, Bardeguez A, Stek A, Read JS, . Obstet Gynecol;116(2 Pt 1):335-?43
Medication adherence in children and adolescents with HIV infection: associations with behavioral impairment.
Malee K, Williams P, Montepiedra G, McCabe M, Nichols S, Sirois PA, Storm D, Farley J, Kammerer B, AIDS Patient Care STDS;25(3):191-?200
First-‐line antiretroviral therapy with a protease inhibitor versus non-‐nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV...
PENPACT-?1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, Gibb DM, Harper L, Harrison L, Hughes M, McKinney R, M..., Lancet Infect Dis;11(4):273-?83
Nonparametric population modeling and Bayesian analysis.
Jelliffe R, Neely MN, Schumitzky A, Bayard D, Van Guilder M, Botnen A, Bustad A, Laing D, Yamada W, Bartroff J, Tatarinova T, Pharmacol Res. 23
Associations of medically documented psychiatric diagnoses and risky health behaviors in highly active antiretroviral therapy-‐ experienced perinatally HIV-‐infected...
Kapetanovic S, Wiegand RE, Dominguez K, Blumberg D, Bohannon B, Wheeling J, Rutstein R; LEGACY Consortium, AIDS Patient Care STDS;25(8):493-?501
Join now to see all

Books/Book Chapters

Principles and Practices of Pediatric Infectious Diseases.
Chapter: The Pharmacokinetic-?Pharmacodynamic Basis of Optimal Antibiotic Dosing
Neely MN, Reed MDEditors: S. Long, L. Pickering, C. Prober.Edition 4,
Principles and Practices of Pediatric Infectious Diseases.
Chapter: The Pharmacokinetic-?Pharmacodynamic Basis of Optimal Antibiotic Dosing
Neely MN, Reed MDEditors: S. Long, L. Pickering, C. Prober.Edition 3,
The Mycota, A Comprehensive Treatise on Fungi as Experimental Systems for Basic and Applied Research: Vol. XII, Studies of Human Fungal Pathogens for the New Millennium.
Chapter: New Azoles
Neely MN, Ghannoum MAEditors: G. Kobayashi, J. Domer.
Principles and Practices of Pediatric Infectious Diseases.
Chapter: The Pharmacokinetic-?Pharmacodynamic Basis of Optimal Antibiotic Dosing
Neely MN, Reed MDEditors: S. Long, L. Pickering, C. Prober.Edition 2,
Join now to see all

Abstracts/Posters

Plasma and Intracellular Lopinavir (LPV) Pharmacokinetics/Pharmacodynamics (PK/PD).
Neely MN, Van Guilder M, Saux M, Jelliffe R, Pellegrin J, Pellegrin I, Fleury H, Breilh D, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Atazanavir concentrations in plasma, breast milk and vaginal secretions of HIV-‐infected women.
Neely MN. Spencer L, Mordwinkin N, Leon T, Louie S, Jelliffe R, Kovacs A, 10th HIV Pharmacology Workshop, Amsterdam
Intensive Pharmacokinetics of Zidovudine, Lamivudine, and Atazanavir and HIV-‐ 1 Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART.
Spencer L, Neely M, Mordwinkin N, Leon T, Fredericks T, Karim R, Louie S, Kovacs A, 16th Conference on Retroviruses and Opportunistic Infections (CROI)
Pharmacometric tools to optimize drug therapy.
Jelliffe RW, Schumitzky A, Bayard D, Leary R, Thomson A, Botnen A, Neely MN, Quantitative & Systems Pharmacology Workshop, National Institutes of Health, Bethesda, MD
Antiviral therapy induces viral and clinical response in patients with central nervous system dysfunction and chromosomally integrated Human Herpesvirus-‐6.
Kar1 AK, Lunn MR, Neely MN, Ambros PF, Troy SB, Montoya JG, 6th International Conference on HHV-?6 & 7
Population Kinetics and Dynamics of Lopinavir in HIV-‐Infected Children.
Neely MN, van den Anker J, Soldin S, Williams K, Baghdassarian A, Rakhmanina N, 17th Population Approach Group in Europe meeting, Copenhagen, Denmark
Population Pharmacokinetic Models and Individualized Bayesian Dose Optimization in HIV Patients.
Neely MN, Jellife RW, 1st American Conference on Pharmacometrics
Recommended Dose of Lopinavir/ritonavir is Sub-‐Optimal in Protease Inhibitor-‐Experienced Children.
Rakhmanina N, van den Anker J, Van Guilder M, Soldin S, Williams K, Baghdassarian A, Neely MN, 15th Conference on Retroviruses and Opportunistic Infections (CROI)
Directly observed therapy for non-‐adherent hiv-‐infected adolescents -‐ lessons learned, challenges ahead.
Gaur AH, Belzer M, Britto P, Garvie P, Hu C, Graham B, Klingman K, Neely MN, McSherry G, and Flynn P, 15th Conference on Retroviruses and Opportunistic Infections (CROI)
Incidence and predictors of disseminated candidiasis associated with candidemia.
Festekjian A, Neely MN, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Lopinavir pharmacokinetics and pharmacodynamics in HIV-‐infected children.
Neely MN, Van Guilder M, van den Anker J, Soldin S, Williams K, Hijada D, Baghdassarian A, Rakhmanina N, 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
The Phenotypic and Genotypic Susceptibility Lopinavir Scores and Virologic Response in Treatment-‐Experienced Children with HIV.
Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely MN, 10th HIV Pharmacology Workshop, Amsterdam
Impact of Lopinavir Limit of Quantification (LOQ)-‐Censored Data Replacement on Population Pharmacokinetic (PK) Plasma and Saliva Modeling in HIV-‐Infected Children.
Neely MN, Rakhmanina N, Van Guilder M, Schumitzky A, Jelliffe R, 16th Population Approach Group in Europe meeting
Saliva concentrations of NRTIs and PIs are better predictors of free than total plasma concentrations in children with HIV infection.
Rakhmanina N, Soldin S, van den Anker J, Williams K, Hijada D, Baghdassarian A, Neely MN, 10th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Nice, France
Pharmacokinetics (PK) and Safety of Caspofungin (CAS) in Young Children Ages 3 to 24 Months.
Neely MN, Jafri H, Seibel N, Knapp K, Adamson P, Bi S, Bradshaw S, Panebianco D, Stone J, Kartsonis N, Pediatric Academic Societies Annual Meeting
Novel Modeling Strategy Using Random Antiretroviral Drug Levels to Measure Adherence in HIV-‐ Infected Patients.
Neely MN, Lam J, Kovacs A, Van Guilder M, Jelliffe R, Louie S, 7th Annual HIV Pharmacology Workshop, Lisbon, Portugal
LC-‐MS/MS Analysis of Protease Inhibitors.
Lam J, Neely MN, Bi L, Louie S, 7th Annual HIV Pharmacology Workshop, Lisbon, Portugal
Novel Atazanavir Immunoassay.
Lam J, Louie S, Valdez J, Moon B, Helms M, Neely MN, 7th Annual HIV Pharmacology Workshop, Lisbon, Portugal
New version of the USC*PACK program for individualized dosage regimens of potentially toxic drugs.
Jelliffe R, Schumitzky A, Bayard D, Milman M, Botnen A, Gandhi A, Van Guilder M, Neely M, Proceedings of the 11th Annual Meeting “Chelovek I Lekarstvo” (Man and Drugs), Moscow, Russia
Caspofungin Pharmacokinetics and Pharmacodynamics in a Neutropenic Guinea Pig Candidiasis Model.
Neely MN, Long LA, Reed MD, Myers C, Blumer JB, Ghannoum MA, 40th Infectious Diseases Society of America annual meeting, Chicago, IL
Colorimetric enhancement of the NCCLS M27 protocol for anti-‐fungal MIC determination.
Neely MN, Ghannoum MA, 40th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, Canada
High-‐dose amoxicillin pharmacokinetics and pharmacodynamics in children.
Neely MN, Reed MD, Jelliffe RW, 19th Population Approach Group in Europe meeting, Berlin, Germany
Population PK-‐ PD of bisphosphonate (BP)-‐related osteonecrosis of the jaw (BRONJ).
Sedghizadeh PP, Le AD, Lee P, Kiss A, Jones A, Jelliffe RW, Neely MN, American College of Clinical Pharmacology Annual Meeting, San Diego, CA
A. Non-‐parametric Bayesian fitting: a novel approach to population pharmacokinetic modeling.
Neely MN, Tatarinova T, Bartroff J, van Guilder M, Yamada W, Bayard D, Jelliffe RW, Schumitzky A, 21st Population Approach Group in Europe meeting, Venice, Italy
Software to enable optimally precise dosage adjustment of voriconazole to achieve predefined serum concentration targets in critically patients.
Hope W, Van Guilder M, Donnelly P, Blijlevens N, Bruggemann R, Jelliffe R, Neely MN, 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, England
Join now to see all

Lectures

Pediatric HIV Case Presentations.
12th HIV Pharmacology Workshop, Miami
Raltegravir.
Maternal Child Adolescent Center, Los Angeles, CA
Clinical Research: Ideas to Results.
Grand Rounds, Department of Pediatrics, LAC+USC Medical Center
Pharmacometric tools for optimally precise individualized drug therapy: non-‐ parametric population modeling, multiple-‐model Bayesian adaptive control and optimal a...
American College of Clinical Pharmacology 38th Annual meeting, San Antonio, TX
Non-‐parametric Pharmacokinetic Modeling.
Department of Haematology, Jagiellonian University, Krakow, Poland
Individualizing Drug Dosage regimens. How to do it with graphical software at the Bedside or Nurses’ Station.
Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Buenos Aires, Argentina
Individualized Dosing – How to do it at the bedside or nurse’s station.
American College of Clinical Pharmacology 39th Annual meeting, Baltimore, MD
Clinical Pharmacometrics.
National Children’s Hospital, Washington DC
Pertussis.
Neonatal M&M Conference, Methodist Hospital, Arcadia, CA
Personalized Medicine and Individualized Doses.
Clinical Pharmacology Unit, Christian Medical College, Vellore, India
Bayesian adaptive control of antimicrobial therapy: Getting the dose right in the 21st Century.
Emerging Pathogens Institute, University of Florida, Gainesville
Multiple Model Adaptive Control – Getting the Dose Right in the 21st Century.
American Conference on Pharmacometrics, San Diego, CA
Voriconazole Pharmacokinetics in Children.
Los Angeles Intercity Pediatric Infectious Diseases Grand Rounds
Does one size fit all? Getting the dose right in the 21st century.
Pediatric Grand Rounds, Los Angeles County – University of Southern California Medical Center
Practical individualized dosing: 21st century therapeutics and the clinical pharmacometrician.
12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Stuttgart, Germa
Getting the dose right in the 21st century.
Department of Pediatrics, University of Alabama at Birmingham
Using R and PMETRICS for non-‐parametric population PK modeling and simulation.
Division of Clinical Pharmacology, University of Alabama at Birmingham
What’s So Hard About Vancomycin? Getting the Dose Right in the 21st Century.
Infectious Diseases Grand Rounds, Harbor-?UCLA Medical Center, Torrance, CA
Introduction to parametric and non-‐parametric population modeling using R.
Advanced Pharmacokinetics, USC School of Pharmacy, Los Angeles, CA
What’s So Hard About Vancomycin? Getting the Dose Right in the 21st Century.
Maternal Child Adolescent Center for Infectious Diseases and Virology, LAC+USC Medical Center, Los A
Population modeling: assay errors, covariate analysis, and continued introduction to programming in R.
PSCI599 – Advanced Pharmacokinetics, USC School of Pharmacy, Los Angeles, CA
Clinical Pharmacometrics: Getting the dose right in the 21st century.
USC School of Pharmacy, Los Angeles, CA
An Introduction to Non-‐Parametric Population PK Modeling and Simulation Using the R Package Pmetrics.
School of Medicine and Pharmacy, Rockefeller Campus, Lyon, France
Thoughtful Dosing of Antifungal Drugs.
Grand Rounds, Rainbow Babies and Children’s Hospital, Cleveland, OH
Candida and Catheters.
PICU Management Conference, University Hospitals of Cleveland
Join now to see all

Other

Pharmacokinetics and pharmacodynamics of once daily raltegravir and atazanavir in healthy volunteers. Master’s Thesis.
Neely MN, University of Southern California
http://digitallibrary.usc.edu
How to complete an overseas elective.
Neely MN, Resident Report
American Academy of Pediatrics
Amblyopia and vernier acuity.
Neely MN, Senior honors thesis
U.C. Berkeley

Press Mentions

Children’s Hospital Los Angeles Receives $2.8 Million Award to Use AI to Predict Precision Dosing for Critically Ill ChildrenDecember 20th, 2022
Myocarditis and COVID-19 Vaccines: The Latest News for Parents and Why Three Children's Hospital Los Angeles Experts Say Vaccinating Your Child Is Still the Safest ChoiceApril 11th, 2022
Children’s Hospital Los Angeles Awarded $2.4 Million to Study Treatment of Respiratory Infections in Children with TracheostomyAugust 23rd, 2021
Join now to see all

Grant Support

Ontogeny Of Voriconazole Pharmaockinetics And MetabolismEunice Kennedy Shriver National Institute Of Child Health &Human Development2012
Plasma And Genital HIV Dynamics In WomenNational Institute Of Allergy And Infectious Diseases2007–2010
Raltegravir Pharmacokinetics With And Without Atazanavir In Healthy AdultsNational Center For Research Resources2009

External Links

Laboratory of Applied Pharmacokineticshttp://www.lapk.org